Panaji Journal

Hunter Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Homology Medicine, Denali Therapeutics, Regenxbio

 Breaking News
  • No posts were found

Hunter Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Homology Medicine, Denali Therapeutics, Regenxbio

March 02
21:53 2023
Hunter Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Homology Medicine, Denali Therapeutics, Regenxbio
The Hunter Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hunter Syndrome pipeline products will significantly revolutionize the Hunter Syndrome market dynamics.

DelveInsight’s “Hunter Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Hunter Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Hunter Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hunter Syndrome Market Insights

 

Hunter Syndrome Overview

Hunter syndrome is also known as Mucopolysaccharidosis type II (MPS II). It is a condition that affects many different parts of the body and mainly affects males. It is a progressive disorder, but the rate of progression varies among affected individuals.

 

Some of the key facts of the Hunter Syndrome Market Report: 

  • The Hunter Syndrome market size was valued at USD 396 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the findings of the National Institute of Health, MPS II is a progressively debilitating disorder that primarily affects males affecting different parts of the body
  • MPS II can present on a spectrum of severity with variable signs and symptoms, resulting into differential diagnosis based on clinical features
  • Bradley et al. conducted a pilot systematic evidence review to establish methodology utility in rare genetic diseases
  • As per the findings of the MPS Society, it is estimated that nearly 6% of the UK population (around 3.5 million people) will be affected by a rare disease at some point in their lives
  • The total diagnosed prevalent population of Hunter Syndrome in the 7 major markets was 1,173 in 2021. In case of Hunter Syndrome patients in the United States, the diagnosed prevalent cases were found to be 519 in 2021 which is anticipated to increase at a CAGR of 0.7% during the forecasted period.
  • Key Hunter Syndrome Companies: Homology Medicine, Denali Therapeutics, Regenxbio, Takeda, JCR Pharmaceuticals, GC Pharma, Regenxbio, Sangamo Therapeutics, ArmaGen , and others
  • Key Hunter Syndrome Therapies: HMI-203, DNL310, RGX-121, SHP-609/ TAK-60, and others
  • The Hunter Syndrome epidemiology based on gender analyzed that Hunter Syndrome rarely affects females

 

Get a Free sample for the Hunter Syndrome Market Report –

https://www.delveinsight.com/sample-request/hunter-syndrome-market

 

Key benefits of the Hunter Syndrome Market report:

  1. Hunter Syndrome market report covers a descriptive overview and comprehensive insight of the Hunter Syndrome Epidemiology and Hunter Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Hunter Syndrome market report provides insights on the current and emerging therapies.
  3. Hunter Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Hunter Syndrome market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Hunter Syndrome market.

 

Download the report to understand which factors are driving Hunter Syndrome epidemiology trends @ Hunter Syndrome Epidemiological Insights 

 

Hunter Syndrome Market  

The dynamics of the Hunter Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Hunter Syndrome pipeline is robust and possess multiple potential drugs in late and mid stage developments to be launched in the near future. JR-141 is currently in the phase III stage of development followed by TAK-609 in phase II clinical development and DNL310, RGX-121, and in phases I/II clinical development.”

 

Hunter Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hunter Syndrome Epidemiology Segmentation:

The Hunter Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hunter Syndrome
  • Prevalent Cases of Hunter Syndrome by severity
  • Gender-specific Prevalence of Hunter Syndrome
  • Diagnosed Cases of Episodic and Chronic Hunter Syndrome

 

Hunter Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hunter Syndrome market or expected to get launched during the study period. The analysis covers Hunter Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hunter Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Hunter Syndrome market share @ Hunter Syndrome market forecast 

 

Hunter Syndrome Therapies and Key Companies

  • HMI-203: Homology Medicine
  • DNL310: Denali Therapeutics
  • RGX-121: Regenxbio
  • SHP-609/ TAK-609: Takeda

 

Hunter Syndrome Market Drivers

  • Robust Pipeline Activity
  • Reimbursement of Elaprase
  • Increasing Awareness of Hunter Syndrome

 

Scope of the Hunter Syndrome Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hunter Syndrome Companies: Homology Medicine, Denali Therapeutics, Regenxbio, Takeda, JCR Pharmaceuticals, GC Pharma, Regenxbio, Sangamo Therapeutics, ArmaGen , and others
  • Key Hunter Syndrome Therapies: HMI-203, DNL310, RGX-121, SHP-609/ TAK-60, and others
  • Hunter Syndrome Therapeutic Assessment: Hunter Syndrome current marketed and Hunter Syndrome emerging therapies
  • Hunter Syndrome Market Dynamics: Hunter Syndrome market drivers and Hunter Syndrome market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hunter Syndrome Unmet Needs, KOL’s views, Analyst’s views, Hunter Syndrome Market Access and Reimbursement 

 

Hunter Syndrome Market Barriers

  • Drawbacks of Elaprase
  • High Cost of Therapy
  • Adverse Events of Current Treatment Options

 

Table of Contents 

1. Hunter Syndrome Market Report Introduction

2. Executive Summary for Hunter Syndrome

3. SWOT analysis of Hunter Syndrome

4. Hunter Syndrome Patient Share (%) Overview at a Glance

5. Hunter Syndrome Market Overview at a Glance

6. Hunter Syndrome Disease Background and Overview

7. Hunter Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Hunter Syndrome 

9. Hunter Syndrome Current Treatment and Medical Practices

10. Hunter Syndrome Unmet Needs

11. Hunter Syndrome Emerging Therapies

12. Hunter Syndrome Market Outlook

13. Country-Wise Hunter Syndrome Market Analysis (2019–2032)

14. Hunter Syndrome Market Access and Reimbursement of Therapies

15. Hunter Syndrome Market Drivers

16. Hunter Syndrome Market Barriers

17.  Hunter Syndrome Appendix

18. Hunter Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Hunter Syndrome treatment, visit @ Hunter Syndrome Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis